Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract...
Cancer
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect...
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
iCAD’s ProFound Detection Version 4.0 Gains FDA Clearance
Provides 22% Overall Improvement in Detecting Challenging and Aggressive Cancer Subtypes and Enables Clinicians to Incorporate a Prior Exam into...
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted...
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and...
Rectify Pharma to Host Virtual R&D Event on RTY-694 for Primary Sclerosing Cholangitis and Other Hepatobiliary Diseases on November 21, 2024
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs),...
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society...
2024 Tsingke High-Impact Literature Compilation – Gene Synthesis
BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number...
Bunkerhill Health AI Powers Cardiovascular Screening at Stamford Health
SAN FRANCISCO, Oct. 21, 2024 /PRNewswire/ -- Stamford Health's Heart & Vascular Institute has announced it will be the first in...
Healthcare Cloud Computing Market to Grow by USD 98.6 Billion from 2024-2028, as Integrated Services Drive Demand with AI-Powered Market Evolution – Technavio
NEW YORK, Nov. 11, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global healthcare cloud...
The Tandem Meetings of ASTCT and CIBMTR Return to Hawai’i From February 12-15, 2025
ASTCT® and CIBMTR® Bring Leading Experts Together to Share Groundbreaking Advancements in Hematopoietic Cell Transplantation, Cellular Therapy and Gene Therapy.CHICAGO,...
Establishment Labs Announces Participation in Upcoming Investment Conferences
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients...
GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology™
Collaboration will leverage GE HealthCare’s legacy and scale of imaging innovation and RadNet’s DeepHealth AI-powered clinical and workflow solutions to...
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Click here to register for investor webcastCompany plans to file its Earnings Report on November 13, 2024 on Form 10-Q...
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Aptevo Therapeutics and Alligator Bioscience report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, more than half of...
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of...